Adagene Reports Promising 2025 Financial Results, Advances Pipeline with FDA Alignment, and Expands Cash Runway with Sanofi Partnership.

Adagene reported 6-month 2025 financial results and provided corporate updates. The company's Phase 1b/2 trial for Muzastotug (ADG126) in MSS CRC showed a 19.4-month median OS in the 10 mg/kg dose cohorts. The FDA has been aligned on Phase 2 and Phase 3 trial design elements, and the company expects to begin enrolling patients in Phase 2 in 2H 2025. A strategic investment of up to $25 million from Sanofi has extended Adagene's cash runway into 2027.